These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

360 related articles for article (PubMed ID: 14581427)

  • 21. Current understanding of the epidemiology and clinical implications of BRCA1 and BRCA2 mutations for ovarian cancer.
    Narod SA; Boyd J
    Curr Opin Obstet Gynecol; 2002 Feb; 14(1):19-26. PubMed ID: 11801872
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pathologic findings in prophylactic oophorectomy specimens in high-risk women.
    Leeper K; Garcia R; Swisher E; Goff B; Greer B; Paley P
    Gynecol Oncol; 2002 Oct; 87(1):52-6. PubMed ID: 12468342
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Time to stop ovarian cancer screening in BRCA1/2 mutation carriers?
    van der Velde NM; Mourits MJ; Arts HJ; de Vries J; Leegte BK; Dijkhuis G; Oosterwijk JC; de Bock GH
    Int J Cancer; 2009 Feb; 124(4):919-23. PubMed ID: 19035463
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of Oophorectomy on Survival After Breast Cancer in BRCA1 and BRCA2 Mutation Carriers.
    Metcalfe K; Lynch HT; Foulkes WD; Tung N; Kim-Sing C; Olopade OI; Eisen A; Rosen B; Snyder C; Gershman S; Sun P; Narod SA
    JAMA Oncol; 2015 Jun; 1(3):306-13. PubMed ID: 26181175
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study.
    Uyei A; Peterson SK; Erlichman J; Broglio K; Yekell S; Schmeler K; Lu K; Meric-Bernstam F; Amos C; Strong L; Arun B
    Cancer; 2006 Dec; 107(12):2745-51. PubMed ID: 17109443
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cancer prevention and screening practices among women at risk for hereditary breast and ovarian cancer after genetic counseling in the community setting.
    Morgan D; Sylvester H; Lucas FL; Miesfeldt S
    Fam Cancer; 2009; 8(4):277-87. PubMed ID: 19347608
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Patient responses to the disclosure of BRCA mutation tests in hereditary breast-ovarian cancer families.
    Lynch HT; Snyder C; Lynch JF; Karatoprakli P; Trowonou A; Metcalfe K; Narod SA; Gong G
    Cancer Genet Cytogenet; 2006 Mar; 165(2):91-7. PubMed ID: 16527602
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term outcomes of BRCA1/BRCA2 testing: risk reduction and surveillance.
    Schwartz MD; Isaacs C; Graves KD; Poggi E; Peshkin BN; Gell C; Finch C; Kelly S; Taylor KL; Perley L
    Cancer; 2012 Jan; 118(2):510-7. PubMed ID: 21717445
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hereditary ovarian cancer--assessing risk and prevention strategies.
    Pavelka JC; Li AJ; Karlan BY
    Obstet Gynecol Clin North Am; 2007 Dec; 34(4):651-65, vii-viii. PubMed ID: 18061862
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort study.
    Domchek SM; Friebel TM; Neuhausen SL; Wagner T; Evans G; Isaacs C; Garber JE; Daly MB; Eeles R; Matloff E; Tomlinson GE; Van't Veer L; Lynch HT; Olopade OI; Weber BL; Rebbeck TR
    Lancet Oncol; 2006 Mar; 7(3):223-9. PubMed ID: 16510331
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Decision analysis of prophylactic surgery or screening for BRCA1 mutation carriers: a more prominent role for oophorectomy.
    van Roosmalen MS; Verhoef LC; Stalmeier PF; Hoogerbrugge N; van Daal WA
    J Clin Oncol; 2002 Apr; 20(8):2092-100. PubMed ID: 11956270
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Presymptomatic DNA testing and prophylactic surgery in families with a BRCA1 or BRCA2 mutation.
    Meijers-Heijboer EJ; Verhoog LC; Brekelmans CT; Seynaeve C; Tilanus-Linthorst MM; Wagner A; Dukel L; Devilee P; van den Ouweland AM; van Geel AN; Klijn JG
    Lancet; 2000 Jun; 355(9220):2015-20. PubMed ID: 10885351
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Occult ovarian tumors in women with BRCA1 or BRCA2 mutations undergoing prophylactic oophorectomy.
    Lu KH; Garber JE; Cramer DW; Welch WR; Niloff J; Schrag D; Berkowitz RS; Muto MG
    J Clin Oncol; 2000 Jul; 18(14):2728-32. PubMed ID: 10894872
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Outcome of risk-reducing salpingo-oophorectomy in BRCA carriers and women of unknown mutation status.
    Manchanda R; Abdelraheim A; Johnson M; Rosenthal AN; Benjamin E; Brunell C; Burnell M; Side L; Gessler S; Saridogan E; Oram D; Jacobs I; Menon U
    BJOG; 2011 Jun; 118(7):814-24. PubMed ID: 21392246
    [TBL] [Abstract][Full Text] [Related]  

  • 35. High risk for ovarian cancer in a prospective series is restricted to BRCA1/2 mutation carriers.
    Maehle L; Apold J; Paulsen T; Hagen B; Løvslett K; Fiane B; Van Ghelue M; Clark N; Møller P
    Clin Cancer Res; 2008 Nov; 14(22):7569-73. PubMed ID: 19010876
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers.
    Scheuer L; Kauff N; Robson M; Kelly B; Barakat R; Satagopan J; Ellis N; Hensley M; Boyd J; Borgen P; Norton L; Offit K
    J Clin Oncol; 2002 Mar; 20(5):1260-8. PubMed ID: 11870168
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A model for estimating ovarian cancer risk: application for preventive oophorectomy.
    Giannakeas V; Sopik V; Shestopaloff K; Iqbal J; Rosen B; Akbari M; Narod SA
    Gynecol Oncol; 2015 Nov; 139(2):242-7. PubMed ID: 26341709
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Histology of prophylactically removed ovaries from BRCA1 and BRCA2 mutation carriers compared with noncarriers in hereditary breast ovarian cancer syndrome kindreds.
    Casey MJ; Bewtra C; Hoehne LL; Tatpati AD; Lynch HT; Watson P
    Gynecol Oncol; 2000 Sep; 78(3 Pt 1):278-87. PubMed ID: 10985881
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Psychosocial issues following a positive result of genetic testing for BRCA1 and BRCA2 mutations: findings from a focus group and a needs-assessment survey.
    Di Prospero LS; Seminsky M; Honeyford J; Doan B; Franssen E; Meschino W; Chart P; Warner E
    CMAJ; 2001 Apr; 164(7):1005-9. PubMed ID: 11314429
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Stopping ovarian cancer screening in BRCA1/2 mutation carriers: effects on risk management decisions & outcome of risk-reducing salpingo-oophorectomy specimens.
    van Driel CM; de Bock GH; Arts HJ; Sie AS; Hollema H; Oosterwijk JC; Mourits MJ
    Maturitas; 2015 Mar; 80(3):318-22. PubMed ID: 25600260
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.